Plasmalogen Replacement | a new paradigm for treating neurodegeneration

Plasmalogens are a specific class of phospholipid that are critical for the structure and function of cell membranes, particularly those of neurons. They are also a primary component of myelin, which is critical for conductance along the axons of nerves.

Stacks Image 44
Plasmalogens contain a unique chemical structure called a vinyl-ether bond that improves the structure of neuronal membranes. Plasmalogens are critical for many neuronal functions including vesicular fusion, which is required for synaptic transmission, proper APP processing, cholesterol transport, and for the activity of many receptors.
We and others have shown that plasmalogen levels are reduced in patients with Alzheimer's disease, Parkinson's disease, and Multiple Sclerosis. There is also a rare pediatric genetic disorder called Rhizomelic Chondrodysplasia Punctata (RCDP), where children are born with an inability to synthesize plasmalogens.

Plasmalogens are synthesized in a part of the cell called the peroxisome. Peroxisome function is known to decline with age, and is likely the contributing factor for the reduced levels observed in the aging population. By providing the body with the proper synthetic peroxisomal building blocks, the body can bypass the deficiency and replenish its plasmalogen levels.

The synthetic plasmalogen restoration technology developed by MLD consists of several plasmalogen precursor prodrugs that are easily converted to plasmalogens by the body.

We believe that plasmalogen replacement therapy will offer new hope to Alzheimer's, Multiple Sclerosis, and Parkinson's patients, as well as children with RCDP. We are currently scaling up the cGMP synthesis of these compounds in anticipation of FDA-IND submissions for Alzheimer's and RCDP in the near future.

We often associate therapeutics with chemicals or drugs that are used to treat diseases after they develop. Our therapeutics are different. They are designed to correct underlying metabolic imbalances, even before symptoms appear.

By eliminating pre-symptomatic metabolic imbalances through metabolic restoration, our goals are to improve, significantly delay, or even prevent Alzheimer's, Parkinson's and Multiple Sclerosis from developing.